SCHEMBL30128675

SCHEMBL30128675

CS(=O)(=O)c1nc(N)n2ncc(Br)c2n1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.38
CHEK1 O14757 2/20 0.38
CCNA2 P20248 2/20 0.38
CCNA1 P78396 2/20 0.38
GSK3B P49841 3/20 0.36
KDR P35968 2/20 0.35
ABL1 P00519 1/20 0.35
TLR7 Q9NYK1 1/20 0.33
ALDH1A1 P00352 2/20 0.32
PKM P14618 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
LMNA P02545 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30363648 0.74 CDK2 (0.45) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL15720337 0.74 TLR8 (0.35) ABL1TLR7
SCHEMBL25140271 0.73 ABL1 (0.35) CDK2GSK3BABL1ALDH1A1KDM4E
SCHEMBL23508113 0.73 GSK3B (0.34) CDK2GSK3BKDRABL1
SCHEMBL21266385 0.72 ALDH1A1 (0.42) GSK3BALDH1A1SMN1; SMN2LMNANPC1
SCHEMBL15719036 0.71 POLB (0.41) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL23497872 0.70 CA12 (0.37) CDK2GSK3BABL1ALDH1A1NPC1
SCHEMBL29792061 0.69 KDR (0.48) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL15232742 0.68 PDE10A (0.39) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL30363736 0.64 KDR (0.49) CDK2CHEK1CCNA2CCNA1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4114837-A1 PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 Bayer Aktiengesellschaft (DE) 2023-01-11 EP disclosed
EP-4114528-A1 IMIDAZOTRIAZINES ACTING ON CANCER VIA INHIBITION OF CDK12 Bayer Aktiengesellschaft (DE) 2023-01-11 EP disclosed